Opexa Therapeutics (ACER) versus The Competition Head to Head Analysis
Opexa Therapeutics (NASDAQ: ACER) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Opexa Therapeutics to similar businesses based on the strength of its earnings, dividends, profitability, risk, analyst recommendations, valuation and institutional ownership.
Risk and Volatility
Opexa Therapeutics has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500. Comparatively, Opexa Therapeutics’ peers have a beta of 6.22, indicating that their average share price is 522% more volatile than the S&P 500.
0.3% of Opexa Therapeutics shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 6.9% of Opexa Therapeutics shares are owned by insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Opexa Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Opexa Therapeutics||$2.90 million||-$7.97 million||-3.70|
|Opexa Therapeutics Competitors||$284.28 million||$34.29 million||135.04|
Opexa Therapeutics’ peers have higher revenue and earnings than Opexa Therapeutics. Opexa Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent ratings and price targets for Opexa Therapeutics and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Opexa Therapeutics Competitors||846||3197||11593||230||2.71|
As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.94%. Given Opexa Therapeutics’ peers higher possible upside, analysts plainly believe Opexa Therapeutics has less favorable growth aspects than its peers.
This table compares Opexa Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Opexa Therapeutics Competitors||-5,303.90%||-432.72%||-39.09%|
Opexa Therapeutics peers beat Opexa Therapeutics on 7 of the 9 factors compared.
About Opexa Therapeutics
Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).
Receive News & Stock Ratings for Opexa Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics Inc. and related stocks with our FREE daily email newsletter.